Proscia Announces Major Expansion In Preclinical R&D To Drive Faster Drug Safety Decisions
Proscia®, a leading provider of digital and computational pathology solutions, has strengthened its position in the $12 billion preclinical research and development (R&D) market. At the center of its expansion, the company is enhancing its flagship Concentriq® for Research, trusted by 14 of the top 20 pharmaceutical companies as a singular software platform for pathology workflows and data, to accelerate Good Laboratory Practice (GLP) and non-regulated drug safety studies.
Preclinical R&D, which demonstrates if a drug is safe to advance to human clinical trials, centers around workflows with higher volumes of pathology data than any other phase of drug discovery and development. Life sciences organizations are now rapidly adopting digital pathology to drive efficiency and quality gains in their routine operations, streamlining collaboration and improving the reproducibility of results.
“Digital pathology is enabling preclinical pathology and R&D teams to do their jobs better,” said Aleksandra Zuraw, Veterinary Pathologist, Digital Pathologist, and Publisher of Digital Pathology Place. “By shifting from microscope to whole slide image, scientists can work more productively and deliver more consistent results.”
Announced today, Proscia is extending the scalable, intuitive Concentriq for Research to increasingly drive preclinical R&D with new features and services including:
“Expanding our solutions for preclinical R&D was an obvious step for us that came in response to growing customer demand,” said Nathan Buchbinder, Proscia’s Chief Product Officer. “These life sciences organizations are making important drug safety decisions that play a key role in getting new therapies to patients. We are now helping them to increasingly realize the efficiency and quality gains that Concentriq for Research delivers as the place where work happens and data lives.”
A modern pathology platform, Concentriq for Research is used by leading pharmaceutical companies, contract research organizations (CROs), and emerging biotechs to drive their research across the R&D value chain. It serves as an enterprise-wide system of record for pathology data and sits at the center of routine operations, enabling diverse workflows, streamlining collaboration, and unlocking new insights with artificial intelligence (AI). In doing so, the platform is enabling life sciences organizations to better tap into their pathology data from discovery to development to advance the next wave of innovation.
To see a live demonstration of the expanded Concentriq for Research, visit Proscia at booth #634 during the Society of Toxicology 62nd Annual Meeting and ToxExpo. Proscia will also be showcasing the new features during a live webinar on Wednesday, May 3 at 11 AM EDT.
Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.
 Wilson, E., Willoughby, R., & Wallach, M. (2016). CRO Industry Primer. Equity Research: Life Science Tools and Diagnostics. Credit Suisse. Retrieved from https://bit.ly/3FzTBWN